Semaglutide and Testosterone Together

A meaningful number of men who need TRT also have significant excess weight or type 2 diabetes. A meaningful number of men on semaglutide, tirzepatide, or other GLP-1 medications also have low testosterone. The two therapies work on different mechanisms, complement each other well, and are safe to combine under appropriate monitoring. This post covers how semaglutide and testosterone interact, when to start each, and what monitoring looks like when a patient is on both.

Semaglutide and Testosterone: Why These Conditions Overlap

Low testosterone and metabolic dysfunction share common roots. Many men have both because the same underlying issues drive them.

Obesity suppresses testosterone. Adipose tissue converts testosterone to estradiol via aromatase. More body fat equals more conversion and lower circulating testosterone.

Insulin resistance suppresses testosterone. Directly affects testicular function and pituitary signaling. Men with type 2 diabetes have low testosterone at much higher rates than men without diabetes.

Low testosterone worsens metabolic dysfunction. Reduced muscle mass, increased fat storage, worsened insulin sensitivity, and lower activity levels all compound the metabolic picture.

Shared risk factors. Aging, sleep apnea, chronic stress, and sedentary lifestyle all contribute to both.

The result: a 50-year-old man carrying 40 pounds of excess weight is likely to have both low testosterone and insulin resistance or diabetes. Addressing only one often produces incomplete results.

What Each Therapy Does

GLP-1 Agonists (Semaglutide, Tirzepatide)

GLP-1 agonists mimic a natural gut hormone that affects appetite and glucose regulation. They:

• Reduce appetite and food cravings
• Slow gastric emptying, increasing satiety
• Improve insulin sensitivity
• Lower HbA1c in diabetic and prediabetic patients
• Produce meaningful weight loss (typically 10 to 20 percent of body weight over 12 months)
• Reduce cardiovascular events in patients with type 2 diabetes and cardiovascular disease

Semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) are the most commonly used. Tirzepatide acts on both GLP-1 and GIP receptors, often producing somewhat greater weight loss than semaglutide alone.

The STEP 1 trial of once-weekly semaglutide for adults with overweight or obesity demonstrated roughly 15 percent mean body weight reduction at 68 weeks, establishing the weight loss efficacy that now drives much of the combined therapy interest.

Testosterone Replacement Therapy

TRT replaces deficient testosterone to restore physiologic levels. It:

• Improves energy, mood, and libido
• Increases lean muscle mass and reduces visceral fat
• Improves insulin sensitivity modestly
• Supports bone density
• Restores sexual function in men whose issues are hormone-driven
• Improves overall quality of life in hypogonadal men

See our post on TRT safety for the broader efficacy and safety picture.

Does Semaglutide Affect Testosterone?

Yes, indirectly. Semaglutide and similar GLP-1 medications do not directly raise testosterone, but the weight loss they produce often does.

Men on semaglutide who lose 15 to 20 percent of body weight typically see testosterone rise 50 to 150 ng/dL as their adipose-driven aromatization and insulin resistance improve. For men with modest-to-moderate low testosterone driven by weight, this can be enough to resolve symptoms without TRT.

However, this is not universal. Men with primary hypogonadism (testicular dysfunction) do not get much testosterone benefit from weight loss because their testes cannot produce adequate testosterone regardless of adipose tissue levels.

Does Testosterone Affect Semaglutide’s Effects?

TRT does not interfere with semaglutide’s mechanism. The two act on entirely different systems (GLP-1 receptor vs androgen receptor) and do not interact pharmacologically.

What TRT does that complements semaglutide:

• Preserves lean muscle during weight loss (reducing the amount of muscle lost alongside fat)
• Improves energy that enables more exercise during weight loss
• Supports bone density, which is at risk during rapid weight loss
• Addresses low-T symptoms that may persist even after weight loss

For a man combining the two, the net effect is typically better body composition outcomes than either alone: more fat loss with less muscle loss, plus the mood and energy benefits of restored testosterone.

Should You Start GLP-1 First or TRT First?

The answer depends on the clinical picture.

Start with TRT first when:

• Testosterone is clearly low with significant symptoms
• Weight is a moderate issue but not the primary concern
• Sexual function and energy are the main complaints
• You are willing to address weight through lifestyle initially

Start with GLP-1 first when:

Other men should start with GLP-1 first when: Weight is the primary issue (BMI over 30 with multiple metabolic problems). Type 2 diabetes or prediabetes is driving the clinical picture. Testosterone is only mildly low (400 to 500 ng/dL range). You want to see if weight loss resolves the testosterone issue before committing to TRT.

Start both together when:

When both conditions are clearly present and significantly impacting quality of life, the typical priorities are: Both conditions are clearly present and significantly impacting quality of life. Rapid improvement is a priority. You have coordinated care that can manage both protocols simultaneously.

Our medical team coordinates both therapies when appropriate. Tactus Health prescribes both GLP-1 medications and TRT, which simplifies the logistics for patients who need combined therapy.

Common Combined Therapy Protocols

For men starting both:

Month 1: Start semaglutide at low dose (0.25 mg weekly typically). Begin TRT at standard starting dose. Monitor for tolerability of both.

Month 2: Titrate semaglutide to 0.5 mg. Continue TRT. First follow-up labs at 6 weeks covering testosterone, estradiol, hematocrit, CBC, HbA1c, lipid panel.

Month 3 to 6: Continue titrating semaglutide based on response and tolerability. Adjust TRT based on symptom and lab response. Significant weight loss typically becoming evident.

Month 6 to 12: Maintenance phase for both. Labs every 3 to 6 months. Ongoing adjustment of either protocol based on individual response.

Beyond 12 months: Decisions about continuing, tapering, or stopping either medication based on clinical goals and response.

Monitoring Combined Therapy

Combined therapy does not require new monitoring categories, but both sets of follow-up must be integrated.

TRT-specific: Testosterone (total and free), estradiol, hematocrit, PSA (age 40+)

Semaglutide-specific: HbA1c, fasting glucose, lipid panel, weight, blood pressure

Both: Kidney function, liver enzymes, thyroid function, overall clinical assessment

The combined monitoring schedule often coincides with standard intervals: baseline, 6 weeks, 3 months, 6 months, every 6 to 12 months thereafter. One lab draw covers everything.

Potential Issues to Watch

The combination is generally well-tolerated, but several situations warrant extra attention.

Muscle mass during rapid weight loss. Men losing weight fast on GLP-1s can lose lean muscle along with fat. TRT plus adequate protein plus resistance training minimizes this. Men not doing those things may lose more muscle than ideal.

Hematocrit plus dehydration. GLP-1s can reduce appetite for fluids along with food. TRT raises hematocrit. Combined, a mildly dehydrated man on TRT plus semaglutide can have a higher hematocrit reading. Hydration matters.

Gastrointestinal side effects. Semaglutide commonly causes nausea, particularly during dose escalation. This can complicate TRT adherence if vomiting affects absorption of any oral medications or injectable protocols.

Rapid changes requiring dose adjustment. Significant weight loss changes TRT pharmacokinetics slightly. Some men need TRT dose adjustment after losing substantial weight because aromatization patterns change.

Thyroid monitoring. GLP-1 medications have specific contraindications in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

The Endocrine Society Clinical Practice Guideline on Testosterone Therapy specifically recommends addressing obesity and metabolic dysfunction alongside TRT when both are present, supporting the combined-therapy approach for patients who need both.

When One Resolves the Other

Some patients on combined therapy experience enough weight loss to resolve their hypogonadism. When a man loses 40+ pounds over 12 months on GLP-1, his testosterone often rises substantially. Some men can then taper or discontinue TRT.

Others find that even after substantial weight loss, their testosterone remains low. This reflects genuine hypogonadism that was not purely weight-driven. These men continue TRT as a long-term treatment.

The only way to know which category you fall into is to try. Weight loss plus time reveals whether your testosterone responds to the lifestyle factor or requires ongoing replacement.

Cost and Access Considerations

Combined therapy adds cost. Some pragmatic notes:

Insurance coverage varies. GLP-1 medications are covered for type 2 diabetes broadly, for obesity increasingly. TRT is covered for documented hypogonadism. Both usually have prior authorization requirements.

Cash-pay options. Compounded semaglutide and tirzepatide are available through telehealth at lower cost. Compounded TRT through GeorgiaPharmacy networks is similarly available. Combined therapy through a single clinic often simplifies logistics.

Not every man needs both. For mild cases of either, single-therapy approaches are often appropriate and cheaper.

See our post on TRT insurance coverage for more on that side.

The Combined Therapy Summary

Semaglutide and testosterone address different mechanisms and work well together. Weight loss from GLP-1 medications often raises testosterone modestly; TRT handles the remaining hormonal need. The combination produces better body composition and metabolic outcomes than either alone in men who need both. Starting sequence depends on the dominant problem. Monitoring integrates both protocols into coordinated follow-up. our medical team prescribes both therapies at Tactus Health and coordinates combined care for patients who need it.

Medically Reviewed By

Dr. Ashar N., DNP, APRN, FNP-C, PMHNP-BC

Co-Founder & Medical Director at Tactus Health. Dual board-certified, with clinical focus on testosterone therapy, hormone optimization, and metabolic health. In-person care in Sugar Hill, GA, and telehealth TRT for Georgia residents.